Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy

Archives of Ophthalmology

Volumn 125, Issue 12, 2007, Pages 1652-1656

  Tsai, Chieh Chih ^a,b,c   Kao, Shu Ching ^a,c   Cheng, Ching Yu ^a,c,e   Kau, Hui Chuan ^c,d   Hsu, Wen Ming ^a,c   Lee, Cheng Feng ^c   Wei, Yau Huei ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Clinical Medicine   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; CORTICOSTEROID; PREDNISOLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; FEMALE; FOLLOW UP; HUMAN; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SMOKING; URINE LEVEL;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL MARKERS; DEOXYGUANOSINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PREDNISOLONE;

EID: 37149024272     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.12.1652     Document Type: Article

References (41)

1. Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroidassociated orbitopathy: evolving rationale for therapy. Arch Ophthalmol. 2002;120(3):380-386.
2. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev. 2003;24(6):802-835.
3. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med. 1993;329(20):1468-1475.
4. Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab. 2003;88(5):1939-1946.
5. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2002;87(1):385-392.
6. Ademoǧlu E, Ozbey N, Erbil Y. Determination of oxidative stress in thyroid tissue and plasma of patients with Graves' disease. Eur J Intern Med. 2006;17(8):545-550.
7. Bednarek J, Wysocki H, Sowinski J. Oxidative stress peripheral parameters in Graves disease: the effect of methimazole treatment in patients with and without infiltrative ophthalmopathy. Clin Biochem. 2005;38(1):13-18.
8. Mano T, Sinohara R, Sawai Y, et al. Effects of thyroid hormone on coenzyme Q and other free radical scavengers in rat heart muscle. J Endocrinol. 1995;145(1):131-136.
9. Asayama K, Kato K. Oxidative muscular injury and its relevance to hyperthyroidism Free Radic Biol Med. 1990;8(3):293-303.
10. Videla LA, Sir T, Wolff C. Increased lipid peroxidation in hyperthyroid patients: suppression by propylthiouracil treatment. Free Radic Res Commun. 1988;5(1):1-10.
11. Venditti P, Balestrini M, Di Meo S, De Leo T. Effect of thyroid state on lipid peroxidation, antioxidant defenses, and susceptibility to oxidative stress in rat tissues. J Endocrinol. 1997;155(1):151-157.
12. Abalovich M, Llesuy S, Gutierrez S, Repetto M. Peripheral parameters of oxidative stress in Graves' disease: the effects of methimazole and 131 iodine treatments. Clin Endocrinol (Oxf ). 2003;59(3):321-327.
13. Whitehouse MW, Cleland LG. Reactive oxygen species and drug therapy for inflammatory diseases. Agents Actions Suppl. 1985;17:177-188.
14. Youssef AA, Baron DN. Leucocyte superoxide dismutase in rheumatoid arthritis. Ann Rheum Dis. 1983;42(5):558-562.
15. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2′- deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387(3):147-163.
16. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf ). 1997;47(1):9-14.
17. Bartley GB, Gorman CA. Diagnostic criteria for Graves' ophthalmopathy. Am J Ophthalmol. 1995;119(6):792-795.
18. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol. 1989;73(8):639-644.
19. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853-860.
20. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with Graves' disease in Chinese of Taiwan. Eye. 2006;20(5):569-573.
21. Loft S, Vistisen K, Ewertz M, Tjonneland A, Overvad K, Poulsen HE. Oxidative DNA damage estimated by 8-hydroxydeoxyguanosine excretion in humans: influence of smoking, gender and body mass index. Carcinogenesis. 1992;13(12):2241-2247.
22. Giacosa A, Filiberti R. Free radicals, oxidative damage and degenerative diseases. Eur J Cancer Prev. 1996;5(5):307-312.
23. Floyd RA. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis. 1990;11(9):1447-1450.
24. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001;61(24):8697-8702.
25. Saccà SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Arch Ophthalmol. 2005;123(4):458-463.
26. Rajesh M, Ramesh A, Ravi PE, et al. Accumulation of 8- hydroxydeoxyguanosine and its relationship with antioxidant parameters in patients with Eales' disease: implications for antioxidant therapy. Curr Eye Res. 2003;27(2):103-110.
27. Kau HC, Tsai CC, Lee CF, Kao SC, Hsu WM, Wei YH. Increased oxidative DNA damage, 8-hydroxydeoxyquanosine, in human pterygium. Eye. 2006;20(7):826-831.
28. Smith TJ, Wang HS, Evans CH. Leukoregulin is a potent inducer of hyaluronan synthesis in cultured human orbital fibroblasts. Am J Physiol. 1995;268(2 pt 1):C382-C388.
29. Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity. 2003;36(6-7):409-415.
30. Chen B, Tsui S, Smith TJ. IL-1β induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol. 2005;175(2):1310-1319.
31. Tsai CC, Kau HC, Kao SC, et al. Pulsatile ocular blood flow in patients with Graves' ophthalmopathy. Eye. 2005;19(2):159-162.
32. Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1β-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid. 1999;9(3):297-303.
33. Burch HB, Lahiri S, Bahn RS, Barnes S. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res. 1997;65(2):311-316.
34. Hiromatsu Y, Yang D, Miyake I, et al. Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 1998;83(1):121-124.
35. Bednarek J, Wysocki H, Sowinski J. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids. Immunol Lett. 2004;93(2-3):227-232.
36. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol. 2000;129(5):618-622.
37. Ludwig PW, Hoidal JR. Alterations in leukocyte oxidative metabolism in cigarette smokers. Am Rev Respir Dis. 1982;126(6):977-980.
38. Marangon K, Herbeth B, Lecomte E, et al. Diet, antioxidant status, and smoking habits in French men. Am J Clin Nutr. 1998;67(2):231-239.
39. Wiersinga W, Prummel MF. Retrobulbar radiation in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1995;80(2):345-347.
40. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21(2):168-199.
41. Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors. 2003;19(3-4):155-163.